From the Boardroom:Option to Purchase Deals

January 12, 2014

Please join veteran life sciences professionals for an insider’s perspective on key considerations regarding option to purchase deals. Our panel of insiders will weigh in on a number of important questions and key issues that arise with this unique structure.

Confirmed speakers include:

  •  Mark Barrett – VP, Head of Strategy & Business Dev., Rare Diseases, Genzyme
  •  Evelyn Douglas – VP, Corporate Dev., Becton, Dickinson and Company
  •  Jon Glazer – Principal, Transaction Advisory Services, Ernst & Young
  •  Marko Zatylny – Partner, Ropes & Gray
  • Christopher Comeau - Partner, Ropes & Gray

Questions? Contact